MX2012012479A - Metodos, composiciones y accesorios para proporcionar un tratamiento terapeutico. - Google Patents

Metodos, composiciones y accesorios para proporcionar un tratamiento terapeutico.

Info

Publication number
MX2012012479A
MX2012012479A MX2012012479A MX2012012479A MX2012012479A MX 2012012479 A MX2012012479 A MX 2012012479A MX 2012012479 A MX2012012479 A MX 2012012479A MX 2012012479 A MX2012012479 A MX 2012012479A MX 2012012479 A MX2012012479 A MX 2012012479A
Authority
MX
Mexico
Prior art keywords
treatment
kits
compositions
methods
providing
Prior art date
Application number
MX2012012479A
Other languages
English (en)
Inventor
Osnat Ashur-Fabian
Aleck Hercbergs
Original Assignee
Osnat Ashur-Fabian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osnat Ashur-Fabian filed Critical Osnat Ashur-Fabian
Publication of MX2012012479A publication Critical patent/MX2012012479A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención abarca un método terapéutico que emplea tratamiento de una enfermedad tal como el cáncer con triyodotronina (T3) junto con un tratamiento antitiroideo tal como tratamiento con un agente antitiroideo, tratamiento con yodo radiactivo y extirpación quirúrgica de todo o parte de la glándula tiroidea. La invención también abarca una composición farmacéutica que comprende T3 y un agente antitiroideo y un kit que comprende la misma.
MX2012012479A 2010-04-28 2011-04-28 Metodos, composiciones y accesorios para proporcionar un tratamiento terapeutico. MX2012012479A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32882510P 2010-04-28 2010-04-28
PCT/IL2011/000346 WO2011135574A1 (en) 2010-04-28 2011-04-28 Methods, compositions and kits for providing a therapeutic treatment

Publications (1)

Publication Number Publication Date
MX2012012479A true MX2012012479A (es) 2013-07-03

Family

ID=44860959

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012012479A MX2012012479A (es) 2010-04-28 2011-04-28 Metodos, composiciones y accesorios para proporcionar un tratamiento terapeutico.

Country Status (11)

Country Link
US (2) US9655984B2 (es)
EP (1) EP2563120B1 (es)
JP (1) JP5921529B2 (es)
KR (1) KR101841304B1 (es)
CN (1) CN102858156B (es)
AU (1) AU2011246851B2 (es)
BR (1) BR112012027463A2 (es)
CA (1) CA2797625C (es)
ES (1) ES2791708T3 (es)
MX (1) MX2012012479A (es)
WO (1) WO2011135574A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105486869A (zh) * 2014-10-08 2016-04-13 江苏维赛科技生物发展有限公司 一种检测动物源食品中甲巯咪唑残留的酶联免疫试剂盒及其应用
US20200222348A1 (en) * 2017-05-08 2020-07-16 Musli Thyropeutics Ltd. Bimodal modified release compositions for cancer treatment
WO2021257806A1 (en) * 2020-06-18 2021-12-23 Fred Hutchinson Cancer Research Center Iodide for treatment of nonthyroidal illness syndrome
CN114605278A (zh) * 2022-02-11 2022-06-10 天津市肿瘤医院（天津医科大学肿瘤医院） T3或其可药用盐在制备脑胶质瘤放化疗药物方面的应用
CN114878840A (zh) * 2022-07-12 2022-08-09 昆明思安生物科技有限公司 磁微粒化学发光测定三碘甲状腺原氨酸试剂盒及检测方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB851610A (en) 1956-03-07 1960-10-19 Gunther Hillman Method for producing iodine derivatives of thyronine
US4426453A (en) 1980-09-18 1984-01-17 Amersham International Limited Derivatives of iodothyronine compounds and their use in an assay for the free iodothyronine compounds
JPH07116031B2 (ja) 1986-09-24 1995-12-13 株式会社アドバンス 制癌剤
US6017958A (en) 1996-06-04 2000-01-25 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
EP1265582A2 (en) 1999-09-29 2002-12-18 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
US6939863B2 (en) * 2002-01-04 2005-09-06 Wei-Jan Chen Prevention of atherosclerosis and restenosis
US7074426B2 (en) * 2002-03-27 2006-07-11 Frank Kochinke Methods and drug delivery systems for the treatment of orofacial diseases
AU2006287531A1 (en) * 2005-09-08 2007-03-15 Shire Llc Prodrugs of T3 and T4 with enhanced bioavailability

Also Published As

Publication number Publication date
WO2011135574A1 (en) 2011-11-03
CA2797625C (en) 2019-08-20
KR101841304B1 (ko) 2018-03-22
US9655984B2 (en) 2017-05-23
AU2011246851B2 (en) 2016-07-21
EP2563120A4 (en) 2015-05-13
KR20130103336A (ko) 2013-09-23
JP2013525422A (ja) 2013-06-20
ES2791708T3 (es) 2020-11-05
US20130129615A1 (en) 2013-05-23
CN102858156A (zh) 2013-01-02
US10398789B2 (en) 2019-09-03
CN102858156B (zh) 2015-09-23
JP5921529B2 (ja) 2016-05-24
CA2797625A1 (en) 2011-11-03
US20170274104A1 (en) 2017-09-28
BR112012027463A2 (pt) 2015-09-29
AU2011246851A1 (en) 2012-11-15
EP2563120A1 (en) 2013-03-06
EP2563120B1 (en) 2020-02-26

Similar Documents

Publication Publication Date Title
PH12015501744A1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
MX346450B (es) Composiciones y métodos para el tratamiento de la enfermedad celíaca.
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
BR112012020304A2 (pt) complexo que alveja tecido, uso de um complexo que alveja tecido, método de tratamento de um corpo de animal humano ou não humano, composição farmacêutica, e, kit
MX2013010343A (es) Composicion y metodos para el transplante de microbiota de colon.
NZ707086A (en) Anti-cd40 antibodies and methods of use
UA103319C2 (en) Thiazole- and oxazole-benzene sulfonamide compounds
BR112014021498A2 (pt) composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
BR112017027954A2 (pt) métodos de tratamento de tumores de célula epitelioide
MX339239B (es) Anticuerpos anti-cd40 y metodos de uso.
EA201390145A1 (ru) Конъюгаты, частицы, композиции и связанные с ними способы
MX355543B (es) Macrociclos peptidomiméticos.
MA34057B1 (fr) Compositions et methodes pour le diagnostic et le traitement d'une tumeur
BR112015011756A2 (pt) inibidores da glutamase e métodos de uso
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MX2019000225A (es) Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
EA201300171A1 (ru) Способы и композиции для терапии рака печени
WO2012024530A3 (en) Therapeutic peptide-polymer conjugates, particles, compositions, and related methods
MY157341A (en) Methods and compositions for treating lung cancer
EA201200046A1 (ru) Новые соединения, фармацевтическая композиция и связанные с ними способы
MX2013000958A (es) Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201492187A1 (ru) Способы лечения солидных опухолей с использованием кофермента q10
WO2012135848A3 (en) Melatonin-based treatment and diagnosis of bile duct disease

Legal Events

Date Code Title Description
FA Abandonment or withdrawal